171 related articles for article (PubMed ID: 32157115)
21. Acetyl-L-Carnitine downregulates invasion (CXCR4/CXCL12, MMP-9) and angiogenesis (VEGF, CXCL8) pathways in prostate cancer cells: rationale for prevention and interception strategies.
Baci D; Bruno A; Cascini C; Gallazzi M; Mortara L; Sessa F; Pelosi G; Albini A; Noonan DM
J Exp Clin Cancer Res; 2019 Nov; 38(1):464. PubMed ID: 31718684
[TBL] [Abstract][Full Text] [Related]
22. CCR2 expression correlates with prostate cancer progression.
Lu Y; Cai Z; Xiao G; Liu Y; Keller ET; Yao Z; Zhang J
J Cell Biochem; 2007 Jun; 101(3):676-85. PubMed ID: 17216598
[TBL] [Abstract][Full Text] [Related]
23. Hormone receptor-independent CXCL10 production is associated with the regulation of cellular factors linked to breast cancer progression and metastasis.
Ejaeidi AA; Craft BS; Puneky LV; Lewis RE; Cruse JM
Exp Mol Pathol; 2015 Aug; 99(1):163-72. PubMed ID: 26079660
[TBL] [Abstract][Full Text] [Related]
24. microRNA 338-3p exhibits tumor suppressor role and its down-regulation is associated with adverse clinical outcome in prostate cancer patients.
Bakkar A; Alshalalfa M; Petersen LF; Abou-Ouf H; Al-Mami A; Hegazy SA; Feng F; Alhajj R; Bijian K; Alaoui-Jamali MA; Bismar TA
Mol Biol Rep; 2016 Apr; 43(4):229-40. PubMed ID: 26907180
[TBL] [Abstract][Full Text] [Related]
25. Cytokines and Chemokines as Mediators of Prostate Cancer Metastasis.
Adekoya TO; Richardson RM
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32585812
[TBL] [Abstract][Full Text] [Related]
26. Molecular Profiling of Pooled Circulating Tumor Cells from Prostate Cancer Patients Using a Dual-Antibody-Functionalized Microfluidic Device.
Yin C; Wang Y; Ji J; Cai B; Chen H; Yang Z; Wang K; Luo C; Zhang W; Yuan C; Wang F
Anal Chem; 2018 Mar; 90(6):3744-3751. PubMed ID: 29464943
[TBL] [Abstract][Full Text] [Related]
27. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone.
Nemeth JA; Harb JF; Barroso U; He Z; Grignon DJ; Cher ML
Cancer Res; 1999 Apr; 59(8):1987-93. PubMed ID: 10213511
[TBL] [Abstract][Full Text] [Related]
28. Molecular phenotyping of circulating tumour cells in patients with prostate cancer: prediction of distant metastases.
Giesing M; Driesel G; Molitor D; Suchy B
BJU Int; 2012 Dec; 110(11 Pt C):E1202-11. PubMed ID: 23046102
[TBL] [Abstract][Full Text] [Related]
29. Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States.
Kelly SP; Anderson WF; Rosenberg PS; Cook MB
Eur Urol Focus; 2018 Jan; 4(1):121-127. PubMed ID: 29162421
[TBL] [Abstract][Full Text] [Related]
30. Micro-RNA-186-5p inhibition attenuates proliferation, anchorage independent growth and invasion in metastatic prostate cancer cells.
Jones DZ; Schmidt ML; Suman S; Hobbing KR; Barve SS; Gobejishvili L; Brock G; Klinge CM; Rai SN; Park J; Clark GJ; Agarwal R; Kidd LR
BMC Cancer; 2018 Apr; 18(1):421. PubMed ID: 29653561
[TBL] [Abstract][Full Text] [Related]
31. Infiltrating bone marrow mesenchymal stem cells increase prostate cancer stem cell population and metastatic ability via secreting cytokines to suppress androgen receptor signaling.
Luo J; Ok Lee S; Liang L; Huang CK; Li L; Wen S; Chang C
Oncogene; 2014 May; 33(21):2768-78. PubMed ID: 23792449
[TBL] [Abstract][Full Text] [Related]
32. Increased expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate cancer metastasis precursor cells.
Berezovskaya O; Schimmer AD; Glinskii AB; Pinilla C; Hoffman RM; Reed JC; Glinsky GV
Cancer Res; 2005 Mar; 65(6):2378-86. PubMed ID: 15781653
[TBL] [Abstract][Full Text] [Related]
33. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
34. Potential establishment of lung metastatic xenograft model of androgen receptor-positive and androgen-independent prostate cancer (C4-2B).
Yamamichi F; Matsuoka T; Shigemura K; Kawabata M; Shirakawa T; Fujisawa M
Urology; 2012 Oct; 80(4):951.e1-7. PubMed ID: 22920407
[TBL] [Abstract][Full Text] [Related]
35. Differential up-regulation of erythropoietin and its receptor in benign and malignant prostatic tissue.
Xu C; Zhou T; He M; Sun Y
Urol Oncol; 2010; 28(3):314-9. PubMed ID: 19070519
[TBL] [Abstract][Full Text] [Related]
36. Proinflammatory CXCL12-CXCR4/CXCR7 Signaling Axis Drives Myc-Induced Prostate Cancer in Obese Mice.
Saha A; Ahn S; Blando J; Su F; Kolonin MG; DiGiovanni J
Cancer Res; 2017 Sep; 77(18):5158-5168. PubMed ID: 28687617
[TBL] [Abstract][Full Text] [Related]
37. Survivin mRNA-circulating tumor cells are associated with prostate cancer metastasis.
Wang H; Yang M; Xu J; Zou B; Zhou Q; Bian J; Wang X
Tumour Biol; 2016 Jan; 37(1):723-7. PubMed ID: 26242261
[TBL] [Abstract][Full Text] [Related]
38. Peroxisome proliferator‑activated receptor γ agonist rosiglitazone inhibits migration and invasion of prostate cancer cells through inhibition of the CXCR4/CXCL12 axis.
Qin L; Gong C; Chen AM; Guo FJ; Xu F; Ren Y; Liao H
Mol Med Rep; 2014 Aug; 10(2):695-700. PubMed ID: 24842333
[TBL] [Abstract][Full Text] [Related]
39. Regulation of prostate cancer progression by the tumor microenvironment.
Shiao SL; Chu GC; Chung LW
Cancer Lett; 2016 Sep; 380(1):340-8. PubMed ID: 26828013
[TBL] [Abstract][Full Text] [Related]
40. Viable circulating metastatic cells produced in orthotopic but not ectopic prostate cancer models.
Glinskii AB; Smith BA; Jiang P; Li XM; Yang M; Hoffman RM; Glinsky GV
Cancer Res; 2003 Jul; 63(14):4239-43. PubMed ID: 12874032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
